Articles in Scholarly Journals [Incomplete List]

1. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients
   European Journal of Clinical Pharmacology, vol. 63, no. 5, pp. 527–528, 2007
2. Adherence to treatment and risperidone metabolism phenotypes
   European Psychiatry, vol. 22, pp. S150–S150, 2007
3. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
   The Pharmacogenomics Journal, Article ID 6500439, 2007
4. Antipsychotic drugs and QTc prolongation: the potential role of
   Expert Opinion on Drug Metabolism & Toxicology, vol. 3, no. 1, pp. 9–19, 2007
5. Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
   Current Drug Targets, vol. 7, no. 12, pp. 1671–1680, 2006
6. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of
   Clinical Chemistry and Laboratory Medicine, vol. 43, no. 3, pp. 275–279, 2005
7. Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods
   Journal of Affective Disorders, vol. 88, no. 2, pp. 235–238, 2005
8. CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans
   Clinical Pharmacology & Therapeutics, vol. 77, no. 2, pp. P24–P24, 2005
9. QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations
   Journal of Psychopharmacology, vol. 18, no. 2, pp. 189–193, 2004
10. Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio,CYP2D6andCYP2C9Genotypes in Psychiatric Patients
    Pharmacopsychiatry, vol. 37, no. 2, pp. 69–73, 2004
11. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
    European Journal of Clinical Pharmacology, vol. 59, no. 12, pp. 869–873, 2004
12. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
    The Pharmacogenomics Journal, vol. 4, no. 6, Article ID 6500278, 3 pages, 2004
13. The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions
    Current Drug Targets, vol. 5, no. 6, pp. 573–579, 2004
14. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
    European Journal of Clinical Pharmacology, vol. 59, no. 3, pp. 221–225, 2003
15. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
    Journal of Chromatography B, vol. 783, no. 1, pp. 25–31, 2003
16. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions
    Journal of Chromatography B, vol. 783, no. 1, pp. 213–219, 2003
17. Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios
    Journal of Chromatography B, vol. 789, no. 2, pp. 437–442, 2003
18. CYP2C9 gene and susceptibility to major depressive disorder
    The Pharmacogenomics Journal, vol. 3, no. 5, Article ID 6500197, 2 pages, 2003
19. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
    European Journal of Clinical Pharmacology, vol. 58, no. 3, pp. 223–224, 2002
20. Relationship between Risperidone and 9-hydroxy-risperidone Plasma Concentrations and CYP2D6 Enzyme Activity in Psychiatric Patients
    Pharmacopsychiatry, vol. 35, no. 6, pp. 231–234, 2002
21. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
    Clinical Pharmacology & Therapeutics, vol. 71, no. 1, pp. 89–98, 2002
22. Therapeutic Drug Monitoring, vol. 23, no. 6, pp. 616–620, 2001